Curium is a global leader in nuclear medicine, providing life-saving diagnostic and therapeutic solutions to over 14 million patients annually. With a presence in over 60 countries, Curium is dedicated to advancing the field of nuclear medicine through innovation, reliability, and a patient-first approach. Our portfolio includes a wide range of radiopharmaceuticals used in imaging and treatment for various conditions such as cancer, and cardiac, neurological and infectious diseases.
Serves as the central hub for global strategy, corporate governance, financial oversight, and key decision-making for Curium's worldwide operations in nuclear medicine.
Located in a prestigious business district in central Paris, likely featuring modern office amenities designed for international collaboration and executive functions. Its prime location offers excellent connectivity and access to a rich business ecosystem.
The Paris HQ likely fosters a dynamic, international, and results-oriented work culture, emphasizing innovation, collaboration across global teams, and a strong commitment to the company's mission of improving patient health.
The Paris headquarters symbolizes Curium's global reach and its position as a leading European-based player in the nuclear medicine industry. Its location in a major European capital facilitates international business, talent acquisition, and stakeholder engagement.
Curium supports a wide range of global functions including research and development, manufacturing of SPECT, PET, and therapeutic radiopharmaceuticals through multiple production sites, extensive quality control and assurance, global supply chain and logistics management, commercial operations, sales and marketing, and regulatory affairs across more than 60 countries. This integrated network ensures the reliable supply of nuclear medicine to patients worldwide.
12-14 Rond-Point des Champs-Elysées Marcel Dassault
Paris
Île-de-France
France
Address: 2703 Wagner Pl, Maryland Heights, MO 63043, USA
Crucial for supplying the North American healthcare system with essential nuclear medicine products, managing regional strategy, and fostering innovation in diagnostic and therapeutic applications.
Address: Westerduinweg 3, 1755 LE Petten, Netherlands
Essential for the European supply chain of medical radioisotopes, ensuring timely delivery of diagnostic products to hospitals and clinics across the region. Plays a vital role in global Mo-99 supply.
Address: Bâtiment 547, CEA Saclay, 91191 Gif-sur-Yvette Cedex, France
Contributes to Curium's innovation pipeline and production capacity in Europe, focusing on specialized diagnostic and therapeutic agents and collaborating with leading research institutions.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Curium Pharma' leadership includes:
Curium Pharma has been backed by several prominent investors over the years, including:
No major C-suite executive hires or exits have been widely reported for Curium Pharma in the strict period of the last 12 months (approx. mid-2023 to mid-2024). The most significant recent top-level change was the CEO transition in early 2023, which falls outside this specific timeframe.
Discover the tools Curium Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Curium Pharma primarily utilizes the `first.last@curiumpharma.com` email format for its employees. This is a common pattern in multinational corporations and ensures a professional and consistent communication style. Other less common formats might exist for specific departments or legacy systems but are not widely prevalent.
first.last@curiumpharma.com
Format
jane.doe@curiumpharma.com
Example
90%
Success rate
Curium Pharma Official Website / PR Newswire • April 23, 2024
Curium announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending PYLCLARI® (piflufolastat (18F)) for the detection of prostate-specific membrane antigen (PSMA)-positive lesions in patients with prostate cancer. This marks a significant step towards making this advanced diagnostic agent available to patients in Europe....more
Curium Pharma Official Website / PR Newswire • February 27, 2024
Curium and Radioisotope Life Sciences (RLS) entered an exclusive agreement for the distribution and commercialization of Curium’s investigational therapeutic candidate Lutetium-177 (Lu-177) PSMA I&T in South Africa, upon marketing authorization. This partnership aims to expand access to innovative radiopharmaceutical therapies for prostate cancer patients in the region....more
Curium Pharma Official Website / Business Wire • November 14, 2023
Curium presented positive results from its Phase 3 ECLIPSE trial for Lutetium (177Lu) PSMA I&T, an investigational targeted radionuclide therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). The data, shared at the European Society for Medical Oncology (ESMO) Congress 2023, demonstrated promising efficacy and a manageable safety profile, highlighting its potential as a future treatment option....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Curium Pharma, are just a search away.